Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and …
MJ Millan, L Maiofiss, D Cussac, V Audinot… - … of Pharmacology and …, 2002 - ASPET
Because little comparative information is available concerning receptor profiles of antiparkinson
drugs, affinities of 14 agents were determined at diverse receptors implicated in the …
drugs, affinities of 14 agents were determined at diverse receptors implicated in the …
S18327 (1-{2-[4-(6-Fluoro-1, 2-benzisoxazol-3-yl) piperid-1-yl] ethyl} 3-phenyl imidazolin-2-one), a Novel, Potential Antipsychotic Displaying Marked Antagonist …
…, V Audinot, A Newman-Tancredi, L Maiofiss… - … of Pharmacology and …, 2000 - ASPET
S18327 was dose-dependently active in several models of potential antipsychotic activity
involving dopaminergic hyperactivity: inhibition of apomorphine-induced climbing in mice, of …
involving dopaminergic hyperactivity: inhibition of apomorphine-induced climbing in mice, of …
On the efficiency of interim analyses applied to nonclinical studies
L Maïofiss-Dullin, N Boussac-Marlière… - Drug information …, 2007 - journals.sagepub.com
Interim analyses, commonly applied in clinical trials, are rarely used in the nonclinical field,
although they are potentially useful for ethical and practical reasons. The purpose of our work …
although they are potentially useful for ethical and practical reasons. The purpose of our work …
Competitive antagonism in pharmacology: A proposed single step evaluation
L Maïofiss, C Thomas-Haimez… - Drug information …, 1997 - journals.sagepub.com
… is the best method, given the many disadvantages of the conventional Schild procedure (l)? …
Assuming a normal distribution of the effects V, a joint log likelihood L( Y ) was developed: …
Assuming a normal distribution of the effects V, a joint log likelihood L( Y ) was developed: …
[CITATION][C] Pansiony trudovykh rezervov: formirovanie sistemy shkol-internatov v 1954–1964 godakh
ML Maiofis - Novoe literaturnoe obozrenie, 2016
[CITATION][C] MARK J. MILLAN, MAURICETTE BROCCO, JEAN-MICHEL RIVET, VALÉRIE AUDINOT, ADRIAN NEWMAN-TANCREDI
L MAIOFISS, S QUERIAUX, N DESPAUX, JL PEGLION… - THE JOURNAL OF …, 2000
[CITATION][C] S-18327, a novel, potential antipsychotic displaying marked antagonist properties at alpha1-and alpha2-adrenergic receptors: II. Functional profile and a …
…, JP Rivet, V Audinot, A Newman-Tancredi, L Maiofiss… - J Pharmacol Exp Ther, 2000
[CITATION][C] The antiparkinsonian agent, piribedil, possesses a distinctive profile of dopamine D-2/D-3 agonist and alpha (2)-adrenoceptor antagonist properties: A …
MJ Millan, D Cussac, L Maiofiss… - Movement …, 2002 - WILEY-LISS DIV JOHN WILEY & …
[CITATION][C] PHYSICAL METHODS OF ANALYSIS
…, RV Borisova, KI Evstratova, SL Maiofis… - Industrial …, 1987 - Consultants Bureau
[CITATION][C] The Chemistry and Technology of Pharmaceutical Chemicals
LS Maiofis - 1964 - Leningrad